{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.95","upperLimit":"3.12","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"TTR is defined as the time interval from the date of the first dose of study treatment to the date of the first documented confirmed response of PR or better up to the alternative therapy in a participant who responded.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide (CYC) 300 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.","id":"OG000","title":"Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)"}],"paramType":"MEDIAN","populationDescription":"Participants from the Response Evaluable Population, defined as participants who received at least 2 of the 3 ixazomib doses during Cycle 1, had measurable disease at Baseline, and at least 1 postbaseline response assessment, who responded.","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Time to Response (TTR) in RRMM Participants","type":"SECONDARY","unitOfMeasure":"months"}